There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tenaya Therapeutics (TNYA – Research Report), Apellis Pharmaceuticals (APLS – Research Report) and Foghorn Therapeutics (FHTX – Research Report) with bullish sentiments.
Tenaya Therapeutics (TNYA)
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Tenaya Therapeutics yesterday and set a price target of $17.00. The company’s shares closed last Thursday at $2.08, close to its 52-week low of $1.64.
According to TipRanks.com, Ijem is a 4-star analyst with an average return of
Tenaya Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $21.00, a 1005.3% upside from current levels. In a report issued on October 26, H.C. Wainwright also maintained a Buy rating on the stock with a $18.00 price target.
See the top stocks recommended by analysts >>
Apellis Pharmaceuticals (APLS)
In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Apellis Pharmaceuticals, with a price target of $67.00. The company’s shares closed last Thursday at $50.46.
According to TipRanks.com, Archila is a 4-star analyst with an average return of
Currently, the analyst consensus on Apellis Pharmaceuticals is a Strong Buy with an average price target of $69.86, implying a 38.1% upside from current levels. In a report issued on October 27, Oppenheimer also maintained a Buy rating on the stock with a $88.00 price target.
Foghorn Therapeutics (FHTX)
In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Foghorn Therapeutics. The company’s shares closed last Thursday at $3.84, close to its 52-week low of $2.84.
According to TipRanks.com, Werber is a 5-star analyst with an average return of
Foghorn Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $19.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TNYA:
- Tenaya Therapeutics announces FDA clearance to begin testing of TN-401
- Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
- Tenaya Therapeutics management to meet virtually with Piper Sandler
- Tenaya Therapeutics presents clinical, preclinical data on TN-301 program
- Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
